Does Rosuvastatin Affect Kidney Function?
Rosuvastatin does not cause clinically significant deterioration of kidney function in most patients, though it can cause benign proteinuria and hematuria, and carries a small increased risk of acute kidney injury in patients without pre-existing chronic kidney disease. 1, 2
Overall Renal Safety Profile
The evidence from guideline consensus demonstrates that rosuvastatin is generally safe for renal function:
- In 72,488 patient-years of follow-up across 36 studies involving over 40,000 patients, renal impairment or failure occurred in only 536 participants (approximately 0.7% per year) 1
- Rates of renal endpoints were higher in patients with baseline risk factors (hypertension, heart failure, diabetes, or eGFR <60 mL/min/1.73 m²), but there was no difference between placebo and rosuvastatin-treated patients, even in these high-risk groups 1
- No difference was observed between the maximal 40 mg dose and 10 mg daily dose 1
- Two meta-analyses showed no deterioration and a trend toward improvement or maintenance of renal function in patients with renal disease 1
Specific Renal Effects to Monitor
Proteinuria and Hematuria (Common but Benign)
The FDA label and guidelines acknowledge an established association with urinary findings:
- Dipstick-positive proteinuria and microscopic hematuria occur more frequently with rosuvastatin, especially at the 40 mg dose 2
- These findings are generally transient and not associated with worsening renal function 2
- The mechanism is thought to be interference with tubular reabsorption of albumin, not indicative of true renal dysfunction 1
- Recent real-world data from 152,101 rosuvastatin users showed 2.9% developed hematuria and 1.0% developed proteinuria over median 3.1 years follow-up 3
Clinical Action: Consider dose reduction if unexplained persistent proteinuria or hematuria develops during routine urinalysis 2
Acute Kidney Injury Risk (Context-Dependent)
There is contradictory evidence regarding acute kidney injury:
Observational data concerns:
- A large retrospective study of >2 million patients found that high-potency statin users (including rosuvastatin 10 mg) were 34% more likely to be hospitalized with AKI within 120 days of starting treatment in patients WITHOUT chronic kidney disease 1
- Paradoxically, patients WITH chronic kidney disease did not show as large an increase 1
However, these administrative database findings appear quite discordant with randomized trial data 1, which showed no increased risk. The guideline consensus emphasizes that the randomized trial evidence is more reliable.
Kidney Failure with Replacement Therapy
Recent real-world data comparing rosuvastatin to atorvastatin showed a modestly increased risk of KFRT (HR 1.15; 95% CI 1.02-1.30) 3, though the absolute risk remains low.
Dosing Recommendations by Renal Function
Per FDA labeling 2:
- Mild to moderate renal impairment (CrCl ≥30 mL/min/1.73 m²): No dose adjustment needed
- Severe renal impairment (CrCl <30 mL/min/1.73 m²) NOT on hemodialysis:
- Start with 5 mg daily
- Maximum dose 10 mg daily
- Monitor for myopathy development
- Dialysis patients: Guidelines suggest NOT initiating statins in prevalent dialysis patients, but continuing if already on therapy at dialysis initiation 4
Important Clinical Pitfall
A substantial 44% of patients with eGFR <30 mL/min/1.73 m² are prescribed high-dose rosuvastatin (20-40 mg daily), exceeding FDA recommendations 3. This represents a common prescribing error that increases risk of adverse effects including myopathy and potential renal complications.
Comparative Considerations
- One study in diabetic patients suggested atorvastatin may have fewer detrimental effects on renal function than rosuvastatin (48.7% vs 38.6% rapid eGFR decline, p=0.029) 5
- However, other studies showed rosuvastatin and atorvastatin both preserved renal function compared to omega-3 fatty acids in HIV patients with CKD 6
- Rosuvastatin showed increased risk of hematuria (HR 1.08), proteinuria (HR 1.17), and KFRT (HR 1.15) compared to atorvastatin in large real-world analysis 3
Monitoring Approach
- Baseline renal function assessment before initiation
- Monitor for unexplained proteinuria or hematuria during routine urinalysis
- If persistent urinary abnormalities develop, consider dose reduction 2
- In patients with severe renal impairment, monitor closely for myopathy as renal dysfunction increases drug exposure 2
- Do not routinely discontinue rosuvastatin for transient, asymptomatic proteinuria or hematuria unless persistent